In patients with RCC + BMs, RANKL inhibition has been shown to block regulatory T‐cell tolerance and enhance anti‐tumor lymphocytic responses, both independently and in combination with standard‐of‐care immunotherapy [5, 23]. This evidence concerns the gene TNFSF11 and renal cell carcinoma.